High-Density Lipoprotein Cholesterol, High-Density Lipoprotein Particle Size, and Apolipoprotein A-I: Significance for Cardiovascular Risk

van der Steeg, Wim A., Holme, Ingar, Boekholdt, S. Matthijs, Larsen, Mogens Lytken, Lindahl, Christina, Stroes, Erik S.G., Tikkanen, Matti J., Wareham, Nicholas J., Faergeman, Ole, Olsson, Anders G., Pedersen, Terje R., Khaw, Kay-Tee, Kastelein, John J.P.·2008·Journal of the American College of Cardiology
DOI 10.1016/j.jacc.2007.09.060

Cited by (374)

Items 101–200 of 374

  1. The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia
    Dick C. Chan, P. Hugh R. Barrett, Gerald Francis Watts · 2013 · Best Practice & Research Clinical Endocrinology & Metabolism
  2. Comparison between Gradient Gel Electrophoresis and Nuclear Magnetic Resonance Spectroscopy in Estimating Coronary Heart Disease Risk Associated with LDL and HDL Particle Size
    Benoît J. Arsenault, Isabelle Lemieux, Jean‐Pierre Després, Nicholas J. Wareham, Erik S.G. Stroes, John J.P. Kastelein, Kay‐Tee Khaw, S. Matthijs Boekholdt · 2010 · Clinical Chemistry
  3. Advances in understanding gender difference in cardiometabolic disease risk
    Altan Onat, Yusuf Karadeniz, Eyyüp Tusun, Hüsniye Yüksel, Ayşem Kaya · 2016 · Expert Review of Cardiovascular Therapy
  4. Reduced HDL function in children and young adults with type 1 diabetes
    Martin Heier, Mark S. Borja, Cathrine Brunborg, Ingebjørg Seljeflot, Hanna Dis Margeirsdottir, Kristian Folkvord Hanssen, Knut Dahl‐Jørgensen, Michael N. Oda · 2017 · Cardiovascular Diabetology
  5. Relationships between cholesterol efflux and high-density lipoprotein particles in patients with type 2 diabetes mellitus
    Hong Chang Tan, E Shyong Tai, Dmitri Sviridov, Paul John Nestel, Cindy Li Whye Ng, Edmund Chan, Yvonne Teo, D.C.H. Wai · 2011 · Journal of clinical lipidology
  6. Low high-density lipoprotein cholesterol: current status and future strategies for management
    Vibhuti N. Singh · 2010 · Vascular Health and Risk Management
  7. Rethinking HDL-C: An In-Depth Narrative Review of Its Role in Cardiovascular Health
    Prinka Perswani, Syed Muhammad Ismail, Hassan Mumtaz, Naseer Uddin, Muhammad Asfand, Ahmed Bazil Bin Khalil, Aisha Ijlal, Shaheer Ellahi Khan, Muhammad Abdullah Usman, Hadia Younas et al. · 2023 · Current Problems in Cardiology
  8. How to improve cardiovascular diseases prevention in Europe?
    Željko Reiner · 2009 · Nutrition Metabolism and Cardiovascular Diseases
  9. An increased high-density lipoprotein cholesterol/apolipoprotein A-I ratio is associated with increased cardiovascular and all-cause mortality
    Ki‐Chul Sung, Seungho Ryu, Sarah H. Wild, Christopher D. Byrne · 2015 · Heart
  10. Cholesteryl ester transfer protein inhibitors: challenges and perspectives
    Theodosios D. Filippatos, Eleftherios Klouras, Fotios Barkas, Moses Elisaf · 2016 · Expert Review of Cardiovascular Therapy
  11. Aortic vascular inflammation in psoriasis is associated with HDL particle size and concentration: a pilot study.
    Yiding Yu, Nikhil H Sheth, Parasuram Melarcode Krishnamoorthy, Babak Saboury, Anna C. Raper, Amanda L. Baer, Rachel Ochotony, Julia Doveikis, Stephanie L. DerOhannessian, Abby Susan Van Voorhees et al. · 2012 · PubMed Central
  12. Effect of Dehydroepiandrosterone Replacement on Lipoprotein Profile in Hypoadrenal Women
    Manivannan Srinivasan, Brian A. Irving, Ketan Dhatariya, Katherine A. Klaus, Stacy J. Hartman, Joseph P. McConnell, K. Sreekumaran Nair · 2008 · The Journal of Clinical Endocrinology & Metabolism
  13. Dyslipidemia and Risk of Coronary Heart Disease: Role of Lifestyle Approaches for Its Management
    Arthur S. Leon, Ulf Gunnar Bronas · 2009 · American Journal of Lifestyle Medicine
  14. High-Density Lipoprotein Particle Number
    Emil M. deGoma, Daniel James Rader · 2012 · Journal of the American College of Cardiology
  15. Cholesteryl Ester Transfer Protein Inhibition in Cardiovascular Risk Management: Ongoing Trials will End the Confusion
    Paul J.W.H. Kappelle, Arie van Tol, Bruce H. R. Wolffenbuttel, Robin P. F. Dullaart · 2010 · Cardiovascular Therapeutics
  16. Visit-to-visit variability of lipid measurements and the risk of myocardial infarction and all-cause mortality: A prospective cohort study
    Xiaoxue Liu, Shouling Wu, Qiaofeng Song, Xizhu Wang · 2020 · Atherosclerosis
  17. Pleiotropic functions of bile acids mediated by the farnesoid X receptor.
    Bojan Stanimirov, Karmen Stankov, Momir Mikov · 2012 · PubMed
  18. Lipids at the Nexus between Cerebrovascular Disease and Vascular Dementia: The Impact of HDL-Cholesterol and Ceramides
    Domenico Sergi, Enrico Zauli, Veronica Tisato, Paola Secchiero, Giorgio Zauli, Carlo Cervellati · 2023 · International Journal of Molecular Sciences
  19. High-density lipoproteins (HDL) composition and function in preeclampsia
    Yael Einbinder, Tal Biron‐Shental, Moran Agassi-Zaitler, Keren Tzadikevitch Geffen, Jacob Vaya, Soliman Khatib, Meital Ohana, Sydney Benchetrit, Tali Zitman‐Gal · 2018 · Archives of Gynecology and Obstetrics
  20. SR-B1, a Key Receptor Involved in the Progression of Cardiovascular Disease: A Perspective from Mice and Human Genetic Studies
    Irene Gracia‐Rubio, César Martı́n, Fernando Civeira, Ana Cenarro · 2021 · Biomedicines
  21. High-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Cardiovascular Disease in United States Adults
    Kyle R. Bilhorn, Yanting Luo, Brian T. Lee, Nathan D. Wong · 2012 · The American Journal of Cardiology
  22. Lipid assessment, metabolic syndrome and coronary heart disease risk
    Benoît J. Arsenault, Jean‐Pierre Després, Erik S.G. Stroes, Nicholas J. Wareham, John J.P. Kastelein, Kay‐Tee Khaw, S. Matthijs Boekholdt · 2010 · European Journal of Clinical Investigation
  23. Daily energy expenditure and cardiovascular risk in Masai, rural and urban Bantu Tanzanians
    Julia Aneth Mbalilaki, Zablon Masesa, S. B. Strømme, Arne Torbjørn Høstmark, Jan Sundquist, Per Erik Wändell, Annika Rosengren, M.-L. Hellénius · 2008 · British Journal of Sports Medicine
  24. Revisiting high-density lipoprotein cholesterol in cardiovascular disease: Is too much of a good thing always a good thing?
    Mohammad Al Zein, Alicia Khazzeka, Alessandro El Khoury, Jana Al Zein, Zoghaib Dima, Ali Hussein Eid · 2024 · Progress in Cardiovascular Diseases
  25. Examining the paradox of high high-density lipoprotein and elevated cardiovascular risk
    Kavisha Singh, Anand K. Rohatgi · 2018 · Journal of Thoracic Disease
  26. Re-evaluation of cholesteryl ester transfer protein function in atherosclerosis based upon genetics and pharmacological manipulation
    Shizuya Yamashita, Yūji Matsuzawa · 2016 · Current Opinion in Lipidology
  27. The Quest for the Optimal Assessment of Global Cardiovascular Risk: Are Traditional Risk Factors and Metabolic Syndrome Partners in Crime?
    Benoît J. Arsenault, Philippe Pîbarot, Jean‐Pierre Després · 2008 · Cardiology
  28. Coronary artery endothelial dysfunction is positively correlated with low density lipoprotein and inversely correlated with high density lipoprotein subclass particles measured by nuclear magnetic resonance spectroscopy
    Monique A. Ford, Joseph P. McConnell, Shahar Lavi, Charanjit S. Rihal, Abhiram Prasad, Gurpreet Singh Sandhu, Stacy J. Hartman, Lilach O. Lerman, Amir Lerman · 2009 · Atherosclerosis
  29. A Standard Lipid Panel Is Insufficient for the Care of a Patient on a High-Fat, Low-Carbohydrate Ketogenic Diet
    Nicholas G. Norwitz, Vyvyane Loh · 2020 · Frontiers in Medicine
  30. HDL metabolism in context: looking on the bright side
    Gerald Francis Watts, P. Hugh R. Barrett, Dick C. Chan · 2008 · Current Opinion in Lipidology
  31. High-density lipoproteins: Marker of cardiovascular risk and therapeutic target
    Peter Paul Toth, Michael H. Davidson · 2010 · Journal of clinical lipidology
  32. Impaired antioxidant HDL function is associated with premature myocardial infarction
    Klaus Distelmaier, Franz Wiesbauer, Hermann Blessberger, Stanislav Oravec, Lore Schrutka, Christina Binder, Elisabeth Dostal, Martin Schillinger, Johann Wojta, Irene Marthe Lang et al. · 2015 · European Journal of Clinical Investigation
  33. Controlling for apolipoprotein A-I concentrations changes the inverse direction of the relationship between high HDL-C concentration and a measure of pre-clinical atherosclerosis
    Ki‐Chul Sung, Sarah H. Wild, Christopher D. Byrne · 2013 · Atherosclerosis
  34. Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid‐Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease
    Ngoc‐Anh Le, Joanne E. Tomassini, Andrew M. Tershakovec, David Neff, Peter W.F. Wilson · 2015 · Journal of the American Heart Association
  35. Specific Nuclear Magnetic Resonance Lipoprotein Subclass Profiles and Central Arterial Stiffness in Type 1 Diabetes Mellitus: A Case Control Study
    Gemma Llauradó, Núria Amigó, Albert Cano, Sílvia Ballesta, Lara Albert, Isabel Mazarico, Sonia Fernández‐Veledo, Juan Pedro‐Botet, Joan Josep Vendrell, José Miguel González-Clemente · 2019 · Journal of Clinical Medicine
  36. Impaired High‐Density Lipoprotein Anti‐Oxidative Function Is Associated With Outcome in Patients With Chronic Heart Failure
    Lore Schrutka, Klaus Distelmaier, Philipp J. Hohensinner, Patrick Sulzgruber, Irene Marthe Lang, Gerald Maurer, Johann Wojta, Martin Hülsmann, Alexander Niessner, Lorenz Koller · 2016 · Journal of the American Heart Association
  37. Comparison of Treatment of Severe High-Density Lipoprotein Cholesterol Deficiency in Men With Daily Atorvastatin (20 mg) Versus Fenofibrate (200 mg) Versus Extended-Release Niacin (2 g)
    Khalid Al‐Rasadi, Zuhier Ahmed Awan, Khalid Al-Waili, Isabelle L. Ruel, Anouar Hafiane, Larbi Krimbou, Jacques J. Genest · 2008 · The American Journal of Cardiology
  38. U-shaped relationship between apolipoprotein A1 levels and mortality risk in men and women
    Christian C Faaborg-Andersen, Chang Liu, Veerappan Subramaniyam, Shivang Desai, Yan V. Sun, Peter W.F. Wilson, Laurence S. Sperling, Arshed Ali Quyyumi · 2022 · European Journal of Preventive Cardiology
  39. HDL-C: Does it matter? An update on novel HDL-directed pharmaco-therapeutic strategies
    Ramprasad Gadi, Aman M. Amanullah, Vincent M. Figueredo · 2012 · International Journal of Cardiology
  40. Maternal Cardiovascular Risk Profile After Placental Abruption
    Jan H.W. Veerbeek, Janine G Smit, Maria P. H. Koster, Emiel D. Post Uiterweer, Bas B. van Rijn, Steven V. Koenen, Arie Franx · 2013 · Hypertension
  41. Association of apolipoprotein M with high-density lipoprotein kinetics in overweight-obese men
    Esther M. M. Ooi, Gerald Francis Watts, Dick C. Chan, Lars B. Nielsen, Peter Plomgaard, Björn Dahlbäck, P. Hugh R. Barrett · 2009 · Atherosclerosis
  42. HDL and cardiovascular risk: is cholesterol in particle subclasses relevant?
    Cathérine Gebhard, David Rhainds, Jean‐Claude Tardif · 2014 · European Heart Journal
  43. Association of Lipoprotein Subfractions and Coronary Artery Calcium In Patient at Intermediate Cardiovascular Risk
    Borut Jug, Jenny Papazian, Robert Lee, Matthew Jay Budoff · 2012 · The American Journal of Cardiology
  44. An alternative pathway of reverse cholesterol transport: The oxysterol 27-hydroxycholesterol
    Oliver Weingärtner, Ulrich Laufs, Michael Böhm, Dieter Lütjohann · 2009 · Atherosclerosis
  45. Increase in Standard Cholesterol and Large HDL Particle Subclasses in Antiretroviral-Naïve Patients Prescribed Efavirenz Compared to Atazanavir/Ritonavir
    Daria Gotti, Bruno Mario Cesana, Laura Albini, Alessandra Calabresi, Ilaria Izzo, Emanuele Focà, Davide Motta, Rita Bellagamba, Rita Fezza, Pasquale Narciso et al. · 2012 · HIV Clinical Trials
  46. High-density lipoprotein therapeutics and cardiovascular prevention
    Sergio Fazio, MacRae F. Linton · 2010 · Journal of clinical lipidology
  47. Cardiovascular complications of type 1 diabetes: update on the renal link
    Trevor John Orchard, Tina Costacou · 2016 · Acta Diabetologica
  48. Effect of Agraz (Vaccinium meridionale Swartz) on High-Density Lipoprotein Function and Inflammation in Women with Metabolic Syndrome
    Catalina Marín-Echeverri, Christopher N. Blesso, María Luz Fernández, Yeisson Galvis-Pérez, Gelmy Luz Ciro-Gómez, Vitelbina Núñez-Rangel, Juan Carlos Aristizábal, Jacqueline Barona-Acevedo · 2018 · Antioxidants
  49. Arachidonate 5-Lipoxygenase Gene Variants Affect Response to Fish Oil Supplementation by Healthy African Americans
    Patrice Armstrong, Darshan Singh Kelley, John W. I. Newman, Frank E. Staggers, Janna Hartiala, Hooman Allayee, Charles Bolt Stephensen · 2012 · Journal of Nutrition
  50. Relationship of High‐Density Lipoprotein Cholesterol With Periprocedural Myocardial Injury Following Elective Percutaneous Coronary Intervention in Patients With Low‐Density Lipoprotein Cholesterol Below 70 mg/dL
    Xiaolin Li, Yuan‐Lin Guo, Cheng‐Gang Zhu, Rui‐Xia Xu, Ping Qing, Na‐Qiong Wu, Lixin Jiang, Bo Xu, Run‐Lin Gao, Jian‐Jun Li · 2015 · Journal of the American Heart Association
  51. Extended regimens of the combined contraceptive vaginal ring containing etonogestrel and ethinyl estradiol: effects on lipid metabolism
    Fernando Augusto Barreiros, Cristina Aparecida Falbo Guazzelli, Ricardo Luís Barbosa, Maria Regina Torloni, Márcia Barbieri, Fabio F. Araujo · 2010 · Contraception
  52. Lipoprotein particles and size, total and high molecular weight adiponectin, and leptin in relation to incident coronary heart disease among severely obese postmenopausal women: The Women's Health Initiative Observational Study
    Rachel H. Mackey, Kathleen M. McTigue, Yue‐Fang Chang, Emma Barinas‐Mitchell, Roger G. Evans, Lesley Fels Tinker, Cora Elizabeth Lewis, JoAnn E. Manson, Marcia L. Stefanick, Barbara V. Howard et al. · 2015 · BBA Clinical
  53. What can complexity do for diabetes management? Linking theory to practice
    Helen Cooper, Robert Geyer · 2009 · Journal of Evaluation in Clinical Practice
  54. Modified and Dysfunctional Lipoproteins in Atherosclerosis: Effectors or Biomarkers?
    Alexander Nikolaevich Orekhov, Igor Alexandrovich Sobenin · 2018 · Current Medicinal Chemistry
  55. The Sizes and Composition of HDL-Cholesterol Are Significantly Associated with Inflammation in Rheumatoid Arthritis Patients
    Ching‐Kun Chang, En‐Pei Isabel Chiang, Kuang‐Hsi Chang, Kuo‐Tung Tang, Po‐Ku Chen, Hei‐Tung Yip, Chu‐Huang Chen, Der‐Yuan Chen · 2023 · International Journal of Molecular Sciences
  56. HDL-cholesterol and prediction of coronary heart disease: Modified by physical fitness?
    Per Torger Skretteberg, Irene Grundvold, Sverre Erik Kjeldsen, Jan Erikssen, Leiv Sandvik, Knut Liestøl, Gunnar Erikssen, Terje Rolf Pedersen, Johan Bodegård · 2011 · Atherosclerosis
  57. HDL Dysfunction Caused by Mutations in apoA-I and Other Genes that are Critical for HDL Biogenesis and Remodeling
    Angeliki Chroni, Dimitris Kardassis · 2018 · Current Medicinal Chemistry
  58. Benefits and Difficulties in Measuring HDL Subfractions and Human Paraoxonase-1 Activity During Statin Treatment
    Mariann Harangi, Ildikó Seres, János Harangi, György Paragh · 2009 · Cardiovascular Drugs and Therapy
  59. Is HDL function as important as HDL quantity in the coronary artery disease risk assessment?
    Sunita Dodani, Deanna G. Grice, Sunil Joshi · 2009 · Journal of clinical lipidology
  60. Extra Virgin Olive Oil Prevents the Age-Related Shifts of the Distribution of HDL Subclasses and Improves Their Functionality
    Alyann Otrante, Amal Trigui, Roua Walha, Hicham Berrougui, Tamàs Fülöp, Abdelouahed Khalil · 2021 · Nutrients
  61. The relationship between serum amyloid A and apolipoprotein A-I in high-density lipoprotein isolated from patients with coronary heart disease
    Dongxue Wang, Hong Liu, Lirong Yan, Ye-Ping Zhang, Xiaoyuan Guan, Zhimin Xu, You-hong Jia, Yishi Li · 2013 · Chinese Medical Journal
  62. HDL Cholesterol and Cardiovascular Outcomes: What Is the Evidence?
    Melvyn Rubenfire, Robert D. Brook · 2013 · Current Cardiology Reports
  63. High plasma high-density lipoprotein levels, very low cardiovascular risk profile, and subclinical carotid atherosclerosis in postmenopausal women
    Shlomo Keidar, Ido Bogner, Aviva Gamliel-Lazarovich, Ronit Leiba, Bianca Fuhrman, Efim Kouperberg · 2009 · Journal of clinical lipidology
  64. High-Density Lipoprotein Cholesterol Efflux, Nitration of Apolipoprotein A-I, and Endothelial Function in Obese Women
    Edward Vazquez, Amar Akhtar Sethi, Lita A. Freeman, Gloria Zalos, Hira Chaudhry, Erin K. Haser, Brittany O. Aicher, Angel M. Aponte, Marjan Guček, Gregory James Kato et al. · 2011 · The American Journal of Cardiology
  65. Essential Fatty Acid and Prostaglandin Metabolism in Sjögren’s Syndrome, Systemic Sclerosis and Rheumatoid Arthritis
    David F. Horrobin · 1986 · Scandinavian Journal of Rheumatology
  66. CSL112 (Apolipoprotein A-I [Human]) Strongly Enhances Plasma Apoa-I and Cholesterol Efflux Capacity in Post-Acute Myocardial Infarction Patients: A PK/PD Substudy of the AEGIS-I Trial
    Charles Michael Gibson, Syed Hassan A. Kazmi, Serge Korjian, Gerald Chi, Adam T. Phillips, Sahar Memar Montazerin, Danielle Duffy, Bo Zheng, Mark A. Heise, Charles L. Liss et al. · 2022 · Journal of Cardiovascular Pharmacology and Therapeutics
  67. Joint effect of high-density lipoprotein cholesterol and low-density lipoprotein cholesterol on the risk of coronary heart disease
    Gang Hu, Yadong Adam Cui, Pekka Jousilahti, Jouko Sundvall, Cynthia J. Girman, Riitta Antikaínen, Tiina K. Laatikainen, Jaakko Tuomilehto · 2011 · European Journal of Preventive Cardiology
  68. The Yin and Yang of High-Density Lipoprotein Cholesterol⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.
    Jacques J. Genest · 2008 · Journal of the American College of Cardiology
  69. New and Emerging Biomarkers in Cardiovascular Disease
    Leah E. Cahill, Monica L. Bertoia, Sarah A. Aroner, Kenneth Jay Mukamal, Majken K. Jensen · 2015 · Current Diabetes Reports
  70. Underappreciated Opportunities for High-Density Lipoprotein Particles in Risk Stratification and Potential Targets of Therapy
    Robert S. Rosenson, Michael H. Davidson, Ngoc‐Anh Le, Jaime Burkle, Ray Pourfarzib · 2015 · Cardiovascular Drugs and Therapy
  71. Association of High‐Density Lipoprotein‐Cholesterol Versus Apolipoprotein A‐I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer‐Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study
    Julian C. van Capelleveen, Andrea E. Bochem, S. Matthijs Boekholdt, Samia Mora, Ron Cornelis Hoogeveen, Christie Mitchell Ballantyne, Paul M. Ridker, Wensheng Sun, Philip J. Barter, Alan R. Tall et al. · 2017 · Journal of the American Heart Association
  72. Targeting endogenous apo A-I—a new approach for raising HDL
    Prediman K. Shah · 2011 · Nature Reviews Cardiology
  73. High Absolute Coronary Disease Risk among Turks: Involvement of Risk Factors Additional to Conventional Ones
    Altan Onat, Günay Can, Gülay Hergenç, Zekeriya Küçükdurmaz, Murat Uğur, Hüsniye Yüksel · 2010 · Cardiology
  74. Extended regimens of the contraceptive vaginal ring versus hormonal oral contraceptives: effects on lipid metabolism
    Cristina Aparecida Falbo Guazzelli, Fernando Augusto Barreiros, Ricardo Luís Barbosa, Maria Regina Torloni, Márcia Barbieri · 2011 · Contraception
  75. Environmental Factors Modifying HDL Functionality
    Christina E. Kostara, Constantine E. Kosmas, Andreas Sourlas, Eliscer Guzman · 2021 · Current Medicinal Chemistry
  76. HDL Is Not Dead Yet
    Shuhui Wang Lorkowski, Jonathan D. Smith · 2022 · Biomedicines
  77. Oligomer Sensor Nanoarchitectonics for “Turn-On” Fluorescence Detection of Cholesterol at the Nanomolar Level
    Vedant Joshi, Sameer Hussain, Sachin Dua, Nishtha Arora, Sajjad Husain Mir, Gaulthier Rydzek, Thangaraj Senthilkumar · 2022 · Molecules
  78. Clinical benefit from pharmacological elevation of high-density lipoprotein cholesterol: meta-regression analysis
    Florence Hourcade‐Potelleret, Silvy Laporte, Valerie Lehnert, Paul Delmar, Renée Benghozi, U Torriani, Reinhold Koch, Patrick Mismetti · 2015 · Heart
  79. A Translational Medicine perspective of the development of torcetrapib: Does the failure of torcetrapib development cast a shadow on future development of lipid modifying agents, HDL elevation strategies or CETP as a viable molecular target for atherosclerosis? A case study of the use of biomarkers and Translational Medicine in atherosclerosis drug discovery and development
    Lei Zhao, Weijun Jin, Daniel James Rader, Chris J. Packard, Giora Feuerstein · 2009 · Biochemical Pharmacology
  80. Plasma lecithin:cholesterol acyltransferase activity modifies the inverse relationship of C-reactive protein with HDL cholesterol in nondiabetic men
    Robin P. F. Dullaart, Frank G. Perton, Paul J.W.H. Kappelle, R. de Vries, Wim J. Sluiter, Arie van Tol · 2009 · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
  81. Non-HDL-C levels and residual cardiovascular risk: Do population-specific precision approaches offer any advantages?
    Byambaa Enkhmaa, Nishant Prakash, Lars Berglund · 2018 · Atherosclerosis
  82. Association Between HDL Cholesterol and QTc Interval: A Population-Based Epidemiological Study
    Rosaria Del Giorno, Sofia Gabutti, Chiara Troiani, Kevyn Stefanelli, Raffaele Falciano, Elisa Graziano, Tommaso Rochat Negro, Luca Gabutti · 2019 · Journal of Clinical Medicine
  83. Antihyperlipidemic effect of Melothria maderaspatana leaf extracts on DOCA—salt induced hypertensive rats
    Chinnadurai Veeramani, Khalid S. Al‐Numair, Chandramohan Govindasamy, Mohammed A. Alsaif, Kodukkur Viswanathan Pugalendi · 2012 · Asian Pacific Journal of Tropical Medicine
  84. Effect of weight loss on HDL-apoA-II kinetics in the metabolic syndrome
    Theodore W. K. Ng, Dick C. Chan, P. Hugh R. Barrett, Gerald Francis Watts · 2009 · Clinical Science
  85. The benefits of measuring the size and number of lipoprotein particles for cardiovascular risk prediction: A systematic review and meta-analysis
    José A. Quesada, Vicente Bertomeu‐González, Domingo Orozco‐Beltrán, Alberto Cordero, Vicente Francisco Gil-Guillén, Adriana López‐Pineda, Rauf Nouni-García, Concepción Carratalá‐Munuera · 2022 · Clínica e Investigación en Arteriosclerosis
  86. Inclusion of endophenotypes in a standard GWAS facilitate a detailed mechanistic understanding of genetic elements that control blood lipid levels
    Qianqian Zhang, Zexi Cai, Marie Lhomme, Goutam Sahana, Philippe Lesnik, Maryse Guérin, Merete Fredholm, Peter Karlskov‐Mortensen · 2020 · Scientific Reports
  87. Sugar-Sweetened Beverage Consumption and Plasma Lipoprotein Cholesterol, Apolipoprotein, and Lipoprotein Particle Size Concentrations in US Adults
    Danielle E. Haslam, Daniel I. Chasman, Gina Marie Peloso, Mark A. Herman, Josée Dupuis, Alice Hinda Lichtenstein, Caren E. Smith, Paul M. Ridker, Paul F. Jacques, Samia Mora et al. · 2022 · Journal of Nutrition
  88. Increased HDL Size and Enhanced Apo A‐I Catabolic Rates Are Associated With Doxorubicin‐Induced Proteinuria in New Zealand White Rabbits
    Victoria López‐Olmos, Elizabeth Carreón‐Torres, María Luna‐Luna, Cristóbal Flores‐Castillo, Miriam Martínez‐Ramírez, Rocío Bautista‐Pérez, Martha Franco, Julio Sandoval, Francisco‐Javier Roldán, Alberto Aranda‐Fraustro et al. · 2016 · Lipids
  89. Is high HDL cholesterol always good?
    ANDERS G. OLSSON · 2008 · Annals of Medicine
  90. Increased Coronary Heart Disease Risk Determined by High High-Density Lipoprotein Cholesterol and C-Reactive Protein: Modulation by Variation in the CETP Gene
    Robin P. F. Dullaart · 2010 · Arteriosclerosis Thrombosis and Vascular Biology
  91. Changes in Lipoprotein Particle Number With Ezetimibe/Simvastatin Coadministered With Extended‐Release Niacin in Hyperlipidemic Patients
    Ngoc‐Anh Le, Ran Jin, Joanne E. Tomassini, Andrew M. Tershakovec, David Neff, Peter W.F. Wilson · 2013 · Journal of the American Heart Association
  92. A comparison of the cardiometabolic profile of black South Africans with suspected non-alcoholic fatty liver disease (NAFLD) and excessive alcohol use
    Mandlenkosi Caswell Zatu, Johannes Marthinus van Rooyen, Du Toit Loots, Minrie Greeff, Aletta Elisabeth Schutte · 2014 · Alcohol
  93. Biomarker Discovery in Atherosclerotic Diseases Using Quantitative Nuclear Magnetic Resonance Metabolomics
    Shuai Ma, Mingfeng Xia, Xin Gao · 2021 · Frontiers in Cardiovascular Medicine
  94. Urine Albumin-Creatinine ratio is associated with prognosis in patients with diabetic foot osteomyelitis
    Jianrong Yang, Jianhao Huang, Suosu Wei, Xing Zhou, Yuechou Nong, Jingxia Sun, Zhenwei Zhai, Weiwei Li, Wensheng Lu · 2021 · Diabetes Research and Clinical Practice
  95. HDL: o yin-yang da doença cardiovascular
    Camila Canteiro Leança, Marisa Passarelli, Edna Regina Nakandakare, Eder C.R. Quintão · 2010 · Arquivos Brasileiros de Endocrinologia & Metabologia
  96. A new ratio for better predicting future death/myocardial infarction than standard lipid measurements in women >50 years undergoing coronary angiography: the apolipoprotein A1 remnant ratio (Apo A1/ [VLDL3+IDL])
    Heidi Thomas May, John R Nelson, Krishnaji R. Kulkarni, Jeffrey L. Anderson, Benjamin Davies Horne, Tami L. Bair, Joseph Brent Muhlestein · 2013 · Lipids in Health and Disease
  97. High-density lipoprotein: A fall from grace?
    Sander I. van Leuven, Erik S.G. Stroes, John J.P. Kastelein · 2008 · Annals of Medicine
  98. High-density lipoprotein cholesterol
    Michael N. Oda · 2015 · Current Opinion in Endocrinology Diabetes and Obesity
  99. HDL subpopulations containing apoA-I without apoA-II (LpA-I) in patients with angiographically proven coronary artery disease
    Agnieszka Kuchta, Adrian Strzelecki, Agnieszka Ćwiklińska, Marcin Gruchała, Zbigniew Zdrojewski, Barbara Kortas‐Stempak, Ewa Wieczorek, Anna Gliwińska, Kamil Dąbkowski, Maciej Jankowski · 2016 · Journal of Cardiology
  100. Everything in Moderation: Investigating the U-Shaped Link Between HDL Cholesterol and Adverse Outcomes
    Marc Allard‐Ratick, Pratik B. Sandesara, Arshed Ali Quyyumi, Laurence S. Sperling · 2019 · US Cardiology Review